key: cord-0938569-fmz9u012 authors: Neale, Holly; Hawryluk, Elena B. title: COVID-19 Pediatric Dermatology date: 2021-05-31 journal: Dermatol Clin DOI: 10.1016/j.det.2021.05.012 sha: 5666b2e5a099a1054f9c30e2982a78386a44cc5c doc_id: 938569 cord_uid: fmz9u012 Children are a unique subset of patients in relation to the COVID-19 pandemic, often presenting asymptomatically, mildly, or atypically when infected with the virus. Manifestations of the skin may be a primary (or the only) presenting sign. Recognizing cutaneous manifestations of COVID-19 in the pediatric population is important to guide appropriate precautions, testing, and management for the patient and close contacts. Whereas some dermatologic signs in children overlap with those seen in adults, other skin findings have been reported with higher frequency in children and in some cases, may be a clue to downstream multisystemic sequelae. In this chapter, we describe the presentation, pathophysiologic theories, and management strategies for cutaneous manifestations of COVID-19 in children. The hands and feet are frequently a site of cutaneous symptoms; findings include erythema, swelling (edema), and desquamation. 28, [38] [39] [40] Mucositis in the forms of papillitis of the tongue (strawberry tongue), 29,41 cheilitis (lips appearing erythematous, swollen, dry, or cracked/fissured), 28, 39, 40, 42 and/or conjunctivitis 29,41 are frequently observed. While some investigations have found no correlation between mucocutaneous findings and worsened disease severity, 29,41 one study reported that mucocutaneous signs were a risk factor for intensive care unit admission, more severe inflammatory marker derangement (CRP, d-dimer, and lymphopenia), and poor presentation with severe tachycardia. 43 Mucocutaneous manifestations typically resolve with treatment of underlying MIS-C. 37 Importantly, mucocutaneous findings associated with fever in a child are nonspecific, and in the setting of negative COVID-19 testing can pose a diagnostic challenge. In addition to dermatologic presentation, awareness of the most common extra-mucocutaneous findings of MIS-C is necessary when evaluating a child for skin eruption in the COVID-19 pandemic. Fever, a critical component of the MIS-C diagnosis, 21 usually precedes mucocutaneous findings, but can occur after or during acute presentation. 29 Other vital sign changes in the form of tachycardia, tachypnea, and hypotension are presenting signs in over three-quarters of affected children. 26, 36 The gastrointestinal system is the most common organ system involved in MIS-C, and signs in the form of abdominal pain, vomiting, and/or diarrhea are noted in 80-92% of cases. 24, 26 J o u r n a l P r e -p r o o f effluvium, which may be related to the infection, a post-infectious sequelae of disease, or associated stress. 51 Though skin findings are nonspecific and non-diagnostic, dermatologists must be aware of MIS-C and potential downstream sequalae. Children who present with a new skin eruption, swollen extremities, or mucous membrane changes during the COVID-19 era would benefit from a full review of systems, vital signs, and in-person exam. If the presentation is suspicious for MIS-C but the patient is otherwise stable, it is appropriate to obtain laboratory testing to assess for COVID-19 infection and markers of inflammation for signs of multiorgan dysfunction, and/or consult subspecialists. 52 Stable patients with cutaneous eruption of unknown etiology during the pandemic may be counseled to monitor for development of accompanying signs of MIS-C. Severely ill children must be evaluated by emergency/critical care for immediate further work-up and management.  Pernio-like-lesions are an inflammatory response to COVID-19 resulting in purpuric and erythematous acral cutaneous surfaces.  Children and young adults are more likely to manifest with pernio-like lesions than older adults.  Pernio-like lesions are typically self-limiting with excellent prognosis, though recurrent skin sequelae are being appreciated. J o u r n a l P r e -p r o o f Traditional pernio, also called chilblains, is an inflammatory reaction of the superficial vasculature on acral cutaneous surfaces (fingers, toes, nose, ears) that is often idiopathic and triggered by cool and/or damp temperatures (primary pernio), or less commonly due to an underlying autoimmune or systemic inflammatory disease (secondary pernio). 53 Outside of the COVID-19 era, pernio is considered a relatively uncommon disease; 54 one study reported only 8 pediatric cases in 10 years, 55 though many consider this reaction to be clinically identified and readily managed with supportive care. Following the start of the COVID-19 pandemic, thousands of children and young adults with no prior history of acral skin changes began to develop asymptomatic, painful, and/or pruritic lesions with striking resemblance to pernio: erythematous, purpuric papules and macules affecting the toes, feet, fingers, and hands ( Figure 3 ; morphologies are discussed in further detail in Chapter 6). The temporal relationship of increased pernio-like cases coinciding with the pandemic alluded to a possible relationship. Thus, "COVID-toes" and "COVID-fingers" terms were coined, and pernio-like lesions have since become the most frequently reported cutaneous manifestation in confirmed or suspected COVID-19 infected individuals across the globe. 56 Younger, healthy people tend to present with pernio-like lesions at higher frequencies than older adults. 57 The median age of pernio-like lesions is the mid-to-late twenties, 56, 58 and 29% of those with pernio-like lesions are children or adolescents. 59 Leading theories aid in explaining the demographical trend towards healthy youth. The immune system of younger individuals has higher amounts of interferon compared to older adults, 11 which provides innate immunity against J o u r n a l P r e -p r o o f viruses. 60 It is known that constitutive type 1 interferon responses lead to autoinflammatory manifestations, including chilblains. 61 Thus, it is possible that when infected with COVID-19, healthy children and young adults mount a strong interferon response, clearing the virus, 62 and subsequently develop pernio-like lesions as a delayed consequence of inflammation. 63, 64 Supporting this theory, it has been found that individuals with pernio-like lesions respond with significantly higher blood levels of interferon alpha when stimulated with immune ligands compared to patients with acute COVID-19 infection. 65 Higher rates of antibody test positivity compared to rates of RNA detection in individuals with pernio-like lesions, 65 in addition to the tendency for delayed presentation of lesions in relation extracutaneous symptoms (table 3) , 56, 59 provide additional support of pernio-like lesions as a post-viral manifestation of COVID-19 infection. Biopsies of pernio-like lesions offer evidence of a primarily inflammatory process. 66 SARS-CoV-2 nasopharyngeal RNA and/or serologic results often fail to demonstrate COVID-19 infection in many cohorts of individuals with pernio-like lesions, 58,67-69 leading to theories that the increase in cases may be coincidental, due to patient/provider/media awareness (confirmation bias), 70 or a result of pandemic lifestyle changes (such as walking barefoot at home more often). 71 However, lack of laboratory positivity may speak more to testing nuances rather than lack of true infection. 72 Cleared infections, 59 failure to look for IgG, IgM, and/or IgA antibodies in serologic testing, 73 or improper timing of testing in relation to disease (i.e. the window between cleared infection and detectable antibodies) 74 are potential reasons why viral testing may read negative following COVID-19 infection. For example, given the theory that pernio-like lesions are a post-viral manifestation, for a child presenting with pernio-like lesions ten days after a mild cough, RNA testing would be negative if the infection was cleared (the median time to undetectable RNA is 14 days, meaning 50% of individuals test negative before then), 75 and antibodies may not yet be detectable (average length to mount response is 1-3 weeks), 76 thus possible that neither test would be positive. In separate analysis of 906 reported cases of confirmed or suspected COVID-19-associated skin manifestations, COVID-19 tests were more likely to be positive if performed earlier in the disease course, and some negative tests were resulted from patients whose skin biopsies demonstrated SARS-CoV-2 RNA. 72 Mounting evidence supports that a negative test does not necessarily rule out an association of pernio skin lesions with COVID-19, 77 and optimal testing times remain an area of ongoing research. While it is indeed possible that select patients manifest idiopathic pernio, the dramatic surge in cases (including in temperate climates), 65 clustering in families and close contacts, 66 in addition to emerging evidence from larger cohorts 59 supports a connection between pernio-like lesions cases and COVID-19. Of patients with pernio-like lesions during the pandemic, 72% have a suspected COVID-19 infection, 59 and up to 30% of those with serologic testing have antibodies to SARS-CoV-2 59,65 (compared to less than 10% in the general U.S. population.) 78 In a series of 7 pediatric cases, COVID-19 viral particles were observed in endothelial cells using electron microscopy of biopsied pernio-like lesions. 79 With time, more readily available COVID-19 tests, and emerging data, it is anticipated that the relationship between the pandemic and pernio-like lesions will become more clear. Table 4 summarizes the different skin findings by etiology that may be related to COVID-19 infection in pediatric patients. Immunohistochemical positivity for SARS-CoV-2 has been found in EM-like, reticulated purpura, and perniotic-like acral lesions. 86, 90 Young individuals with such acral manifestations tend to have an uncomplicated disease course and excellent outcomes. Non-acral surfaces are also involved in cutaneous eruptions related to COVID-19 infection in children. Some manifestations that are observed in COVID-positive adults such as erythematous, vesicular, or urticarial exanthems 92 can also present in infants and children with suspected or confirmed SARS-CoV-2 infection. 15, [93] [94] [95] Petechiae, which are associated with several other viral illness in children, 96 have been observed in 1-2% of hospitalized COVID-19 positive children and may be widespread or localized. 14 Case reports of children with COVID-19 further demonstrate the various forms of potential mucocutaneous changes, such as erythematous and purpuric macules on the face, 97 swelling and papillitis of the tongue, 98 vesicular oral eruption, 99 a roseola-like rash, 100 and a pruritic maculopapular rash. 100 Notably, these case reports do not support causality between COVID-19 and cutaneous eruptions, as there are many potential causes for exanthems in children. However, the virus has been further implicated by its demonstration in biopsy tissue from various eruptions, including patients with erythema multiforme 86 Whereas some pediatric dermatologic manifestations of SARS-CoV-2, such as the polymorphous rash, mucositis, and conjunctivitis seen in MIS-C, may serve a clue towards serious sequalae, the majority of cutaneous eruptions in relation to the pandemic are benign. Despite the continually evolving understanding of COVID-19 and its potential manifestations, cutaneous eruptions are fortunately most often self-limited and not associated with poor outcomes; some studies even report children with skin rashes have a better prognosis than children with COVID-19 and no rash. 41 With ongoing cases and data reports, the interaction between COVID-19 and the skin in pediatric patients will become better understood. Beyond the dermatologic manifestations of COVID-19 in the pediatric population, our children and adolescents face numerous consequences of the pandemic and some are only starting to be appreciated, ranging from physical impacts such as obesity associated with changes in diet and activity or progression of myopia during home confinement to a wide range of psychosocial consequences of school closures and home/health stressors. 104 As new, potentially more contagious, strains of COVID-19 arise such as the B.1.1.7 variant, there has been concern for how this impacts the pediatric population. From February 2021 to April 2021, there was more than double the frequency of pediatric cases (all age groups) in Michigan, 105 with several other states following similar trends. 106 Though these rises coincide with the emergence of new variants, there is no evidence that new variants preferentially infect children. 107 It is likely that such increases in pediatric cases reflect vaccination and social trends. State-Level Data Report. Accessed Clinical and Imaging Features of COVID-19 in a Neonate Presenting symptoms of COVID-19 in children: a meta-analysis of published studies Systematic Severe Acute Respiratory Syndrome Coronavirus 2 Screening at Hospital Admission in Children: A French Prospective Multicenter Study SARS-CoV-2 Infection in Children Epidemiological characteristics of 2143 pediatric patients with Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors The cellular composition of the human immune system is shaped by age and cohabitation COVID-19: Loss of bridging between innate and adaptive immunity? Med Hypotheses Rash as a presenting complaint in a child with COVID-19 Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: A diagnostic clue? Acute Acro-Ischemia in the Child at the Time of COVID-19 proposal of diagnostic criteria of pernio (chilblains) in a series of 104 patients at Mayo Clinic National Organization for Rare Disorders) Childhood pernio and cryoproteins Skin manifestations of COVID-19: A worldwide review Acral cutaneous lesions in the time of COVID-19 Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing* Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries Principles of Effective and Robust Innate Immune Response to Viral Infections: A Multiplex Network Analysis Type I interferonopathies in pediatric rheumatology Type I IFN immunoprofiling in COVID-19 patients COVID-19) infection-induced chilblains: A case report with histopathologic findings When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients with Chilblain-like Lesions during the COVID-19 Clustered cases of acral perniosis: Clinical features, histopathology, and relationship to COVID-19 The management of the outbreak of acral skin manifestations in asymptomatic children during COVID-19 era Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents during the COVID-19 Pandemic Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review The Profound Dermatological Manifestations of COVID-19: Part IV -Cutaneous Feaures. American Academy of Dermatology Association Major cluster of paediatric 'true' primary chilblains during the COVID-19 pandemic: a consequence of lifestyle changes due to lockdown Timing of PCR and antibody testing in patients with COVID-19-associated dermatologic manifestations A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection Detection of antibodies against SARS-CoV-2 in patients with COVID-19 Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19 COVID-19 Serology Surveillance Strategy | CDC. Accessed Emerging Evidence of the Direct Association between COVID-19 and Chilblains Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases Outbreak of chilblain-like acral lesions in children in the metropolitan area of Milan, Italy, during the COVID-19 pandemic Erythema Pernio-like in four Adolescents in the era of the Coronavirus-2 Infection Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients Chilblainlike lesions in pediatrics dermatological outpatients during the COVID-19 outbreak Images in Practice: Painful Cutaneous Vasculitis in a SARS-Cov-2 IgG-Positive Child Relapse of chilblain-like lesions during the second wave of COVID-19. J Eur Acad Dermatology Venereol Erythema multiforme-like lesions in children and COVID-19 Acral purpuric lesions (erythema multiforme type) associated with thrombotic vasculopathy in a child during the COVID-19 pandemic Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak The management of the outbreak of acral skin manifestations in asymptomatic children during COVID -19 era Suspected COVID-19-related reticulated purpura of the soles in an infant Livedo reticularis and acrocyanosis as late manifestations of COVID-19 in two cases with familial aggregation Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019). An Pediatría (English Ed Clinical characteristics of children with viral single-and co-infections and a petechial rash Cutaneous manifestations in COVID -19: A skin rash in a child Cutaneous manifestations in COVID-19: A skin rash in a child Oral vesicles and acral erythema: report of a cutaneous manifestation of COVID-19 Appearance of skin rash in pediatric patients with COVID-19: Three case presentations Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report Acute disseminated encephalomyelitis in a COVID-19 pediatric patient SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics Progression of Myopia in School-Aged Children after COVID-19 Home Confinement Children and COVID-19: State Data Report.; 2021 COVID-19 Response Reporting. Online New Variants of Coronavirus: What You Should Know. Online AAP helps pediatricians prepare to vaccinate children, adolescents against COVID-19. AAP News Multi-System Inflammatory Syndrome in a Child Mimicking Kawasaki Disease Epidemiologic features of Kawasaki disease in Taiwan The global epidemiology of Kawasaki disease: Review and future perspectives Kawasaki disease: etiopathogenesis and novel treatment strategies Associated Symptoms in the Ten Days Before Diagnosis of Kawasaki Disease Describing Kawasaki shock syndrome: results from a retrospective study and literature review Acral lesions in a pediatric population during the COVID-19 pandemic: a case series of 36 patients from a single hospital in Spain Management of pernio-like cutaneous manifestations in children during the outbreak of COVID-19 Chilblains in children in the setting of COVID-19 pandemic A case of covid-19 with late-onset rash and transient loss of taste and smell in a 15-year-old boy Immunological and virological profile of children with chilblain-like lesions and SARS-CoV-2. J Eur Acad Dermatology Venereol Multisystem inflammatory syndrome in children: A systematic review Abbreviations: Multisystem inflammatory syndrome in children (MIS-C)